Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

AIDS Research and Human Retroviruses
L S WyattB Moss

Abstract

Recombinant modified vaccinia virus Ankara (MVA) expressing SIV or SHIV Gag-Pol and Env, alone or in conjunction with a related DNA vaccine, effectively controls immunodeficiency virus infections in nonhuman primates. Here we describe the construction, characterization, and immunogenicity of MVA/HIV 48, a candidate HIV-1 clade B Gag-Pol-Env vaccine. A novel transfer vector was designed to allow the incorporation of HIV genes regulated by vaccinia virus promoters together with a reporter gene into a single site in the MVA genome and to automatically delete the reporter after the initial isolation of the recombinant MVA. MVA/HIV 48 contains chimeric HIV-1 HXB-2/BH10 gag-pol sequences, a deletion of integrase, inactivating point mutations in reverse transcriptase, and HIV-1 ADA env sequences with a truncation of most of the cytoplasmic domain to enhance expression on the plasma membrane. Cells infected with MVA/HIV 48 expressed HIV proteins, which were processed to the expected size. The Env was inserted into the plasma membrane and was functional in a CCR5 coreceptor-dependent cell fusion assay. Moreover, virus-like particles were released into the medium and budding particles containing Env were visualized by immunoelectron micr...Continue Reading

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G Sutter, B Moss
Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·L Yuen, B Moss
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·B Moss
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·E Paoletti
Jun 8, 1999·Annual Review of Immunology·E A BergerJ M Farber
Apr 20, 2000·The Journal of Clinical Investigation·M J MastrangeloE C Lattime
Apr 3, 2001·Science·D Paydarfar, W J Schwartz
May 2, 2002·Vaccine·Tomás HankeRachel V Samuel

❮ Previous
Next ❯

Citations

Jul 10, 2004·AIDS Research and Human Retroviruses·James M SmithHarriet L Robinson
Feb 2, 2011·The Journal of Infectious Diseases·Paul A GoepfertUNKNOWN National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network
Jan 10, 2014·The Journal of Infectious Diseases·Paul A GoepfertUNKNOWN National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network
Oct 16, 2004·Reviews in Medical Virology·Linh X DoanQizhi Yao
Sep 26, 2006·Methods : a Companion to Methods in Enzymology·Kelly R YoungTed M Ross
Jul 6, 2016·The Journal of Experimental Medicine·Karin SteinbachDoron Merkler
Dec 3, 2016·The Journal of Experimental Medicine·Andreas MuschaweckhGeorg Gasteiger
Feb 6, 2009·The Journal of Gene Medicine·Kandan AravindaramNing-Sun Yang
Aug 26, 2017·Expert Review of Vaccines·Lynette Siv Chea, Rama Rao Amara
Jul 25, 2014·PLoS Neglected Tropical Diseases·James Weger-LucarelliJorge E Osorio
Sep 25, 2019·Vaccines·Sarah WilmschenJanine Kimpel
Dec 20, 2005·The Journal of General Virology·Richard H ClarkGeoffrey L Smith
Jan 15, 2021·The Journal of Immunology : Official Journal of the American Association of Immunologists·Vineet JoagDavid Masopust

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.